Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexaria Bioscience Corp (LXX.CN)

Lexaria Bioscience Corp (LXX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 42,270
  • Shares Outstanding, K 5,104
  • Annual Sales, $ 706 K
  • Annual Income, $ -11,902 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.81
  • Price/Sales 28.56
  • Price/Cash Flow N/A
  • Price/Book 2.99
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.86
  • Most Recent Earnings $0.09 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.620 +10.24%
on 06/10/21
9.010 -6.77%
on 06/28/21
-0.140 (-1.64%)
since 06/08/21
3-Month
5.800 +44.83%
on 04/20/21
10.610 -20.83%
on 05/06/21
+1.520 (+22.09%)
since 04/08/21
52-Week
5.100 +64.71%
on 01/12/21
20.700 -59.42%
on 07/20/20
-2.250 (-21.13%)
since 07/08/20

Most Recent Stories

More News
Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets

KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Announces 2021 Annual Meeting Results

KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs

DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Provides Progress Report on Six R&D Programs

- All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine - These studies are part of Lexaria's 2021 applied...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1

- Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria’s Patented Technology for Hypertension Relief - Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus

KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that remdesivir...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever

- New formulation delivers up to 2,708% more CBD into bloodstream* - Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted

- New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX)...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET

Lexaria Recently Announced Favorable Data on Its First Animal Study, As Well as the Commencement of Its First Human Clinical Study, Under Its 2021 Hypertension R&D Program KELOWNA, BC / ACCESSWIRE / May...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1

- Up to 2,178% more CBD delivered into bloodstream* - Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)...

LEXXW : 0.0012 (-77.36%)
LEXX : 0.8000 (+8.74%)
LXX.CN : 8.400 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs,...

See More

Key Turning Points

3rd Resistance Point 8.400
2nd Resistance Point 8.400
1st Resistance Point 8.400
Last Price 8.400
1st Support Level 8.400
2nd Support Level 8.400
3rd Support Level 8.400

See More

52-Week High 20.700
Fibonacci 61.8% 14.741
Fibonacci 50% 12.900
Fibonacci 38.2% 11.059
Last Price 8.400
52-Week Low 5.100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar